Empowering Immunotherapy Companion Diagnostics
Precise.Validated TMB Reference Standards for tissue and liquid biopsy assays
Product Center
CBP80001-1/2/3/4/5/6/7/8
CBP80001-1/2/3/4/5/6/7/8
Product Introduce
Tumor Mutational Burden (TMB) Reference Standards
TMB measures the number of somatic mutations per megabase of the tumor genome. It is a validated pan-cancer biomarker for immune checkpoint inhibitor response (FDA-approved for TMB-H ≥10 mut/Mb).
CB-Gene’s TMB diagnostic reference standards are designed to help IVD developers and clinical labs accurately assess the limit of detection, linearity, and reproducibility of their TMB assays. Our portfolio includes tissue-simulating (tTMB) and blood-based (bTMB) standards, with TMB scores ranging from 5.37 to 27.15 mut/Mb – including critical values around the 10 mut/Mb clinical cutoff.
Product Advantages
Precisely quantify tumor mutational burden with our complete panel of tissue and blood-based reference standards. Validated by WES, covering a full TMB range (5–27 mut/Mb) to support assay development, regulatory submission, and routine quality control.
Gold-standard validation
TMB scores derived from whole-exome sequencing (WES) compared to matched normal samples.
Wide gradient coverage
Low, medium, and high TMB values (5.37, 8.98, 9.84, 12.41, 21.09, 22.91, 27.15 mut/Mb) for linearity and accuracy studies.
tTMB & bTMB formats
Both tissue-mimicking reference standards and circulating tumor DNA (ctDNA) blood-based standards.
Limit-of-detection assessment
Available with different tumor content percentages and allele frequency (AF) cutoffs.
Matrix control
Negative/matrix standard (CBP80001-9) for background evaluation.
Application
IVD Kit Development & Performance Verification
Testing Sensitivity, Accuracy & Specificity of Experimental Methods
Daily QC Monitoring of NGS Library Preparation & Sequencing Runs
Company Advantage
We stands out with a strong foundation in precision diagnostics and a commitment to high-quality, reliable products
Scientific Quality Management
With our ISO9001 certification, we adhere to a stringent quality management system, ensuring that all our products meet the highest standards of accuracy, stability, and consistency.
Experienced and Skilled Team
Backed by a talented team of experts, we leverage advanced technology and extensive experience to drive innovation in molecular diagnostics, ensuring we stay at the forefront of the industry.
Advanced Laboratories
Our lean laboratories, located in Shanghai and Nanjing, China, are equipped to provide continuous and stable high-quality products, supporting both large-scale production and personalized customer needs.
Comprehensive Product Range
We offer a complete set of reference materials, including SNP, Indel, CNV, Fusion, NIPT, and more, covering a wide array of diagnostic needs and offering customized services for a variety of applications.
Contact Us
We're here to assist you! Whether you have questions about our products, services, or need technical support, our team is ready to provide you with the information you need. Reach out to us today!
FAQs
Related Blogs
ATP7B Reference Standards for Multi-Platform Wilson Disease Assay Validation
For laboratories developing and validating genetic tests for Wilson disease (WD), selecting appropriate ATP7B reference standards is an important part of establishing a controlled and reproducible assay. Wilson disease testing may use Sanger sequencing, quantitative real-time PCR (qPCR), droplet digital PCR (ddPCR), or targeted next-generation sequencing (NGS). Each workflow requires well-characterized genomic DNA reference materials to evaluate analytical performance, monitor run-to-run consistency, and support reliable ATP7B variant detection and genotyping. Suitable ATP7B reference standards should have clearly defined genotypes and variant identities, a relevant sample matrix, compatibility with the intended method, and characteristics aligned with the laboratory's validation plan. This article reviews the principal considerations when selecting ATP7B reference standards for multi-platform Wilson disease assay validation.
Read More
PSMA IHC Control Standards for IHC Assay Development and Quality Control
PSMA IHC control standards are critical reference materials for prostate cancer pathological diagnosis and targeted therapy testing. Featuring positive/negative 2‑in‑1 FFPE tissue design, they support simultaneous positive control, negative control, background evaluation, and staining specificity verification. Suitable for assay development, inter‑batch reproducibility monitoring, routine QC, and external quality assessment.
Read More
HLA Reference Standards for Assay Validation and Quality Control: A Practical Guide
HLA genotyping assays must deliver accurate, reproducible, and clearly interpretable results across different samples, reagent lots, operators, instruments, and laboratories. This requirement is especially important because HLA genes are highly polymorphic, and even a small difference in amplification, sequencing, allele assignment, or result interpretation may affect the final genotype call.
Read More
PCR-SSP, PCR-SBT, Sanger, NGS, or TGS: Which HLA Typing Method Fits Your Assay?
HLA typing methods differ in the way they detect alleles, the amount of sequence information they generate, the number of loci they can process, and the level of laboratory infrastructure they require. A method that works well for a rapid, targeted HLA test may not be suitable for a high-resolution transplantation workflow or a multi-locus research panel.
Read More
Get Touch With Us
Contact Info
Have questions or need assistance? We're here to help! Reach out to our team, and we'll provide the support you need.
